# A Phase II Study of Tislelizumab Plus Anlotinib Consolidation After Chemoradiotherapy in LS-SCLC

Source: https://onco.cc/trials/nct07815223/  
OnCo record `nct07815223` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of tislelizumab and anlotinib in lung cancer, run by Yantai Yuhuangding Hospital, now recruiting.

## Summary

A Phase II Study of Tislelizumab Plus Anlotinib Consolidation After Chemoradiotherapy in LS-SCLC is a phase 2, interventional study registered as NCT07815223 by Yantai Yuhuangding Hospital, with a registry enrolment figure of 20 participants, started 2025-11-04 and due to reach its primary completion in 2028-12-31. Interventions recorded: Tislelizumab + Anlotinib. Conditions listed: SCLC, Limited Stage. Primary outcome: Progression Free Survival (PFS); Overall Survival (OS). Lung eligibility wording from the registry: "Have histologically or cytologically confirmed small-cell lung cancer;". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-25
- Tags: ctgov-ingest; lung-deep-dive
- Registry id: NCT07815223
- Phase: 2
- Setting: A Prospective, Single-Arm, Phase II Study of Tislelizumab Plus Anlotinib as Consolidation Therapy in Patients With Limited-Stage Small Cell Lung Cancer Without Progression After Concurrent or Sequential Chemoradiotherapy
- Sponsor: Yantai Yuhuangding Hospital
- Enrolled: 20

## Sources

- ClinicalTrials.gov NCT07815223: https://clinicaltrials.gov/study/NCT07815223

## Connected records

- cancers: [Limited-stage small-cell lung cancer](https://onco.cc/cancers/limited-stage-sclc/)
- technologies: [Anti-angiogenic therapy](https://onco.cc/technologies/antiangiogenic/), [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/), [IMRT / IGRT (modern external beam)](https://onco.cc/technologies/imrt-igrt/), [Small-molecule kinase inhibitors](https://onco.cc/technologies/kinase-inhibitors/)
- drugs: [Anlotinib](https://onco.cc/drugs/anlotinib/), [Tislelizumab](https://onco.cc/drugs/tislelizumab/)
- companies: [BeOne Medicines (formerly BeiGene)](https://onco.cc/companies/beone/), [Sino Biopharmaceutical (Chia Tai Tianqing)](https://onco.cc/companies/sino-biopharm/)
- terms: [Lung cancer trials open today (registry snapshot)](https://onco.cc/terms/lung-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07815223.json